Company Overview
| Stock Name | Guanze Medical |
|---|---|
| Stock Code | 02427 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家立足於山東省的醫學影像解決方案供應商,主要從事提供醫用影像膠片產品及醫學影像雲服務。 |
| Listing Date | 2022-12-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 山東省濟南市高新區春暉路2966號濟南高新區戰略性新興產業基地10座501-A室 |
| Business Address (Hong Kong) | 德輔道西246號東慈商業中心8樓02室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | guanzegroup.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 0.53 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 5,000 shares |
| Entry Threshold | HK$ 2,650 |
| Par Value | To be extracted |
| Offer Period | 2022-12-15 to 2022-12-20 |
| Global Offering Shares | 192,850,000 shares |
| HK Public Offer Shares (Initial) | 19,285,000 shares (10.0%) |
| Public Offer Lots (Initial) | 3,857lots (Pool A1,928lots,Pool B1,929lots) |
| International Placing Shares (Initial) | 173,565,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 950,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 29.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 102,210,500 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 5,000 | HK$ 2,650 |
| 2 lots | 10,000 | HK$ 5,300 |
| 3 lots | 15,000 | HK$ 7,950 |
| 4 lots | 20,000 | HK$ 10,600 |
| 5 lots | 25,000 | HK$ 13,250 |
| 6 lots | 30,000 | HK$ 15,900 |
| 7 lots | 35,000 | HK$ 18,550 |
| 8 lots | 40,000 | HK$ 21,200 |
| 9 lots | 45,000 | HK$ 23,850 |
| 10 lots | 50,000 | HK$ 26,500 |
| 12 lots | 60,000 | HK$ 31,800 |
| 14 lots | 70,000 | HK$ 37,100 |
| 16 lots | 80,000 | HK$ 42,400 |
| 18 lots | 90,000 | HK$ 47,700 |
| 20 lots | 100,000 | HK$ 53,000 |
| 30 lots | 150,000 | HK$ 79,500 |
| 40 lots | 200,000 | HK$ 106,000 |
| 50 lots | 250,000 | HK$ 132,500 |
| 60 lots | 300,000 | HK$ 159,000 |
| 70 lots | 350,000 | HK$ 185,500 |
| 80 lots | 400,000 | HK$ 212,000 |
| 90 lots | 450,000 | HK$ 238,500 |
| 100 lots | 500,000 | HK$ 265,000 |
| 120 lots | 600,000 | HK$ 318,000 |
| 140 lots | 700,000 | HK$ 371,000 |
| 160 lots | 800,000 | HK$ 424,000 |
| 180 lots | 900,000 | HK$ 477,000 |
| 200 lots | 1,000,000 | HK$ 530,000 |
| 300 lots | 1,500,000 | HK$ 795,000 |
| 400 lots | 2,000,000 | HK$ 1,060,000 |
| 700 lots | 3,500,000 | HK$ 1,855,000 |
| 800 lots | 4,000,000 | HK$ 2,120,000 |
| 1,400 lots | 7,000,000 | HK$ 3,710,000 |
| 1,600 lots | 8,000,000 | HK$ 4,240,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.72B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +258% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 503,500,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣23.1百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue | 184,435 | 106,728 | 98,621 |
| Cost of sales | -122,860 | -70,340 | -58,995 |
| Gross profit | 61,575 | 36,388 | 39,626 |
| Other income and gains, net | 745 | 1,283 | 1,640 |
| Selling and distribution expenses | -16,957 | -11,624 | -12,253 |
| Administrative expenses | -3,878 | -9,246 | -6,552 |
| Profit before tax | 39,003 | 16,033 | 21,494 |
| Income tax expense | -9,960 | -4,866 | -6,092 |
| Profit for the year | 29,043 | 11,167 | 15,402 |
| Profit attributable to owners | 29,043 | 11,095 | 15,316 |
Balance Sheet
| Item | 2019 | 2020 | 2021 | 2022-06 | 2022 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 5,521 | 20,235 | 14,925 | ||
| Trade and bills receivables | 96,630 | 137,249 | 166,861 | ||
| Inventories | 21,632 | 12,571 | 3,428 | ||
| Total current assets | 125,867 | 173,488 | 199,554 | ||
| Total assets | 153,885 | 204,051 | 232,047 | ||
| Total current liabilities | 51,633 | 41,337 | 53,955 | ||
| Total liabilities | 55,445 | 41,491 | 54,085 | ||
| Total equity | 98,440 | 162,560 | 177,962 | ||
| Equity attributable to owners | 98,440 | 162,397 | 177,713 | ||
| Interest-bearing borrowings | 1,000 | 8,313 | 15,000 | 1,509 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021 | 2022-06 | 2022 |
|---|---|---|---|---|---|
| Net cash from operating activities | 28,168 | 4,579 | -2,278 | ||
| Net cash from investing activities | -9,831 | -7,856 | -4,168 | ||
| Net cash from financing activities | -19,310 | 17,991 | 1,136 | ||
| Net increase in cash | -973 | 14,714 | -5,310 | ||
| Depreciation of PP&E | 1,119 | 2,208 | 3,275 | 1,990 | |
| Depreciation of right-of-use assets | 133 | 255 | 310 | 155 | |
| Amortisation of intangible assets | 816 | 824 | 833 | 418 | |
| Purchase of PP&E | -7,490 | -7,811 | -11,541 | -45 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 1.75 |
|---|---|
| First Day Open | HK$ 1.2 |
| First Day Change | 230.19% |
| First Day Volume | 63010000.0 |
| First Day Turnover | 92718800.0 |
| Use of Proceeds | 1、約34.0百萬港元(約46.4%)將用于延伸至山東省東部,以擴闊客戶基礎及進一步鞏固于山東省的市場地位;
2、約27.4百萬港元(約37.3%)將用于藉由策略性收購、取得醫療器械注冊證及將軟硬件升級以加強醫學影像云服務的供應;
3、約2.0百萬港元(約2.7%)將用于擴大產品組合以橫向擴充價值鏈;
4、約1.8百萬港元(約2.5%)將用于藉由參與交易會、貿易展覽及會議,不斷推廣我們的品牌及增加市場知名度;
5、約1.8百萬港元(約2.5%)將用于我們的信息科技系統升級;
6、約6.3百萬港元(約8.6%)將用作額外營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
Southwest Securities (HK) Capital Limited CE AIC042
Overall Coordinators (3)
Joint Bookrunners (10)
SOUTHWEST SECURITIES (HK) BROKERAGE LIMITED CE ACB501
GOLDLINK SECURITIES LIMITED CE BHH779
Funde Securities Limited CE BHT984
交银国际证券有限公司 CE APJ121
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
SPDB International Capital Limited CE BFZ375
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Alpha Financial Group Limited CE ALW542
Apricot Capital (Hong Kong) Limited CE ACX624
Joint Lead Managers (11)
SOUTHWEST SECURITIES (HK) BROKERAGE LIMITED CE ACB501
GOLDLINK SECURITIES LIMITED CE BHH779
Funde Securities Limited CE BHT984
交银国际证券有限公司 CE APJ121
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
SPDB International Capital Limited CE BFZ375
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Alpha Financial Group Limited CE ALW542
Apricot Capital (Hong Kong) Limited CE ACX624
I WIN SECURITIES LIMITED CE BJB315
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Carsonlin Investment Ltd | 22,111,600 HKD | — | 21.60% | — | 6 months | 2023-06-29 |
| 2 | 慕敏 | 2,210,100 HKD | — | 2.20% | — | 6 months | 2023-06-29 |
| 3 | 杨新云 | 5,527,900 HKD | — | 5.40% | — | 6 months | 2023-06-29 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 孟憲震 | — |
| Company Secretary | 張森泉 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Meng A Capital、孟憲震先生及楊段玲女士於緊隨資本化發行及全球發售完成後分別持有本公司已發行股本約74.96%(假設超額配股權未獲行使)。 |
|---|




